Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Hello, and welcome to Regeneron Pharmaceuticals' fourth quarter 2024 earnings conference call. My name is Tawanda, and I will be your operator for today's call. (Operator Instructions) Please note ...

and payers may create barriers to adoption if they perceive limited additional benefit. The success of this transition is crucial for maintaining Eylea franchise revenues, but it remains uncertain ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from ...

Total Play Telecomunicaciones, S.A.P.I. de C.V. ("Total Play," "we," "us" or "our") today announced the early results with respect to its previously announced (x) offer to exchange (the "Exchange ...

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.09%, and the Nasdaq ...

Regeneron’s gene therapy for a profound form ... at Cambridge University Hospitals NHS Foundation Trust in the UK. “With these very preliminary DB-OTO results, we now have encouraging evidence ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...